BRISBANE, Calif.--(BUSINESS WIRE)--Tercica, Inc. (Nasdaq:TRCA) today announced that a jury in the US District Court for the Northern District of California found that Insmed Incorporated and Insmed Therapeutic Proteins, Inc. have infringed Genentech’s US Patent No. 5,258,287; willfully infringed US Patent No. 5,187,151; and upheld the validity of Genentech’s US Patent No. 6,331,414 (the ‘414 Patent). Tercica exclusively licensed these patents in April 2002 for use in its manufacture and sale of, among other things, Increlex™. Prior to the trial, the Court had ruled that Insmed’s process for making the IGF-1 in IPLEX™ literally infringes three claims of the ‘414 Patent, and Insmed had stipulated that it infringes on three additional claims.
